Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Galantamine: a review of its use in Alzheimer's disease.

Scott LJ, Goa KL.

Drugs. 2000 Nov;60(5):1095-122. Review.

PMID:
11129124
3.

Current status and new developments with galantamine in the treatment of Alzheimer's disease.

Tariot P.

Expert Opin Pharmacother. 2001 Dec;2(12):2027-49. Review.

PMID:
11825333
4.

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Aronson S, Van Baelen B, Kavanagh S, Schwalen S.

Drugs Aging. 2009;26(3):231-9. doi: 10.2165/00002512-200926030-00004.

PMID:
19358618
5.

Donepezil: a review of its use in Alzheimer's disease.

Dooley M, Lamb HM.

Drugs Aging. 2000 Mar;16(3):199-226. Review.

PMID:
10803860
6.

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.

Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D.

J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):589-95.

7.

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.

Drugs Aging. 2004;21(7):453-78. Review.

PMID:
15132713
8.

Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease.

Wilkinson D, Murray J.

Int J Geriatr Psychiatry. 2001 Sep;16(9):852-7.

PMID:
11571763
9.

Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.

Lyseng-Williamson KA, Plosker GL.

Pharmacoeconomics. 2002;20(13):919-42.

PMID:
12381243
10.

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.

Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S.

Dement Geriatr Cogn Disord. 2003;15(2):79-87.

PMID:
12566596
11.

Galantamine hydrobromide: an agent for Alzheimer's disease.

Zarotsky V, Sramek JJ, Cutler NR.

Am J Health Syst Pharm. 2003 Mar 1;60(5):446-52. Review.

PMID:
12635450
12.
13.

Clinical pharmacokinetics of galantamine.

Farlow MR.

Clin Pharmacokinet. 2003;42(15):1383-92. Review.

PMID:
14674789
14.

Galantamine: additional benefits to patients with Alzheimer's disease.

Lilienfeld S, Parys W.

Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Review.

PMID:
10971048
15.
16.

Clinical profile of donepezil in the treatment of Alzheimer's disease.

Doody RS.

Gerontology. 1999;45 Suppl 1:23-32. Review.

PMID:
9876215
17.

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C.

Neurology. 2000 Jun 27;54(12):2269-76.

PMID:
10881251
18.

Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.

Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, Fasanaro AM, Trequattrini A; Upgrade Study Group..

Curr Med Res Opin. 2005 Nov;21(11):1809-18.

PMID:
16307702
19.

[Galantamine: a novel cholinergic agent for Alzheimer's disease].

Olazarán J, García G.

Neurologia. 2002 Oct;17(8):429-36. Spanish.

PMID:
12396973
20.

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.

Chianella C, Gragnaniello D, Maisano Delser P, Visentini MF, Sette E, Tola MR, Barbujani G, Fuselli S.

Eur J Clin Pharmacol. 2011 Nov;67(11):1147-57. doi: 10.1007/s00228-011-1064-x.

PMID:
21630031
Items per page

Supplemental Content

Support Center